The purpose of this study is to investigate the effect of impaired liver function on the drug levels, safety, and tolerability of BMS-986036 in participants with moderate and severe liver impairment. Results from this study will be used to determine whether dose adjustment is required for patients with decreased liver function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Specified dose on specified days
Local Institution - 0002
Miami, Florida, United States
Local Institution
Orlando, Florida, United States
Local Institution - 0001
San Antonio, Texas, United States
Maximum observed plasma concentration (Cmax)
Time frame: Up to 29 days
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 29 days
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC(0-T))
Time frame: Up to 29 days
Number of participants with adverse events (AEs)
Time frame: Up to 31 days
Number of participants with clinical laboratory abnormalities
Time frame: Up to 31 days
Number of participants with vital sign abnormalities
Time frame: Up to 31 days
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to 31 days
Number of participants with physical examination abnormalities
Time frame: Up to 31 days
Maximum observed plasma concentration (Cmax)
Time frame: Up to 29 days
Time of maximum observed plasma concentration (Tmax)
Time frame: Up to 29 days
Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration(AUC(0-T))
Time frame: Up to 29 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.